Yuhan Corporation Receives 72.3 Billion KRW in Secondary Royalties for Lazertinib

[Asia Economy Reporter Minwoo Lee] Yuhan Corporation announced on the 23rd that it received $65 million (approximately 72.3 billion KRW) in milestone payments from Janssen Biotech, a subsidiary of the global pharmaceutical company Johnson & Johnson.

This milestone payment was triggered by the initiation of Phase 3 clinical trials for the combination therapy of EGFR-targeted anticancer drug 'Layertinib,' licensed to Janssen, and Janssen's anticancer drug 'Amivantamab.'

Yuhan Corporation also received the first milestone payment of $35 million in April. With this recent payment, the total milestone payments have reached $100 million. This amount exceeds the $50 million upfront payment from the Layertinib licensing agreement.

Previously, in November 2018, Yuhan Corporation licensed the global rights to Layertinib, excluding South Korea, to Janssen for a total of $1.255 billion.

This content was produced with the assistance of AI translation services.